Centene Corp (CNC) Earnings: FY Adjusted EPS Forecast Reaffirmed at $2+ Ahead of UBS 2025 Conference

Centene Corp on Smartkarma

Analysts on Smartkarma are closely following Centene Corp, a leading managed care organization for U.S. government-sponsored health insurance. Recent reports by Value Investors Club and Baptista Research shed light on the company’s current performance and future outlook. According to Value Investors Club, Centene Corp has faced challenges, including a $1.8 billion shortfall in financial guidance, leading to a stock price drop to $32. Despite this, there is optimism about a potential EPS rebound to $7.06 in 18-24 months, hinting at a $70 share price. On the other hand, Baptista Research highlights Centene’s first-quarter achievements in 2025, emphasizing the balance between growth prospects and operational challenges within its various segments, with an adjusted diluted EPS of $2.90 for the quarter.

A look at Centene Corp Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Centene Corporation, a multi-line managed care organization, appears to have a positive long-term outlook based on an analysis using Smartkarma Smart Scores. With a top score in Value, Centene is seen as a strong contender in terms of its financial standing and potential. Despite a lower score in Dividend, the company’s focus on growth, resilience, and momentum indicates promising aspects for its future performance.

Overall, Centene’s diversified portfolio of health plans in multiple states, coupled with its specialty services like behavioral health and nurse triage, position it well for growth. While the company may have room for improvement in dividend payouts, its solid performance in other key areas suggests a bright future ahead.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma